KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Common Equity: 2020-2024

Historic Common Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $1.0 billion.

  • Recursion Pharmaceuticals' Common Equity rose 99.59% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 99.59%. This contributed to the annual value of $1.0 billion for FY2024, which is 123.28% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Common Equity stood at $1.0 billion for FY2024, which was up 123.28% from $463.4 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Common Equity peaked at $1.0 billion during FY2024, and registered a low of -$206.3 million during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median Common Equity value was $485.8 million (recorded in 2022), while the average stood at $661.3 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Common Equity skyrocketed by 363.19% in 2021 and then dropped by 10.52% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Common Equity (Yearly) stood at -$206.3 million in 2020, then surged by 363.19% to $542.9 million in 2021, then declined by 10.52% to $485.8 million in 2022, then dropped by 4.60% to $463.4 million in 2023, then spiked by 123.28% to $1.0 billion in 2024.